NICE draft guidance does not recommend Evrysdi for SMA
3rd June 2021
The UK National Institute for Health and Care Excellence (NICE) has announced that it does not recommend Roche’s Evrysdi for the treatment of spinal muscular atrophy (SMA) in draft guidance.
Evrysdi (risdiplam) is licensed for the treatment of patients with types 1, 2 and 3 SMA in the EU.
In a statement, NICE said that although clinical trials demonstrate that Roche’s drug meaningfully improves motor function for these patients, the long-term benefits are uncertain.
The committee also added that the oral administration of Evrysdi is ‘innovative’, as it offers an alternative for patients who cannot receive other SMA treatments and allows for home administration.
Pragmatic but flawed: the NICE guideline on chronic pain thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
NICE green lights Tremfya to treat active psoriatic arthritis
28th May 2021
Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s National Institute for Health and Care Excellence (NICE) for the treatment of active psoriatic arthritis (PsA).
Tremfya (guselkumab) is a fully human monoclonal antibody (mAb) designed to selectively bind to and inhibit the IL-23 receptor – an key driver of progression in inflammatory diseases such as PsA.
NICE’s final appraisal document (FAD) recommends Tremfya to treat moderate-to-severe PsA in adults who have responded inadequately to disease-modifying antirheumatic drug (DMARD) therapy or who cannot tolerate them.
We know that for the outcomes that matter to patients, ivermectin, hydroxychloroquine, zinc, steroids and remdesevir offer no real benefits against non-severe disease.